AKT1 and diffuse large B-cell lymphoma: Recent studies showed constitutive activation of the PI3K/AKT pathway in 25–52% of DLBCL patients, and correlated overexpression of phosphorylated Akt (pAKT) with significantly poorer progression-free survival in approximately one-fourth of DLBCL patients [17].